CRL

NEUTRALEarnings

Charles River Laboratories Inte

2026-09-03

Price

$293.35

+0.54%

This is the 2026-09-03 snapshot — the signals and analysis for CRL as of this single trading day.

View full CRL research hub →

Score4.6Watchlist

Signals3/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.8xvs 20d avg

Analysis

Charles River Laboratories (CRL) is demonstrating robust institutional absorption, shrugging off valuation concerns and insider selling to consolidate near 52-week highs. The technical setup features a PERFECT_STACK and MARKET_LEADER profile, structurally supported by a recent Q2 earnings beat, raised guidance, and a new vaccine development partnership with Medigen Vaccine Biologics. With the macro regime firmly RISK_ON (RATES) and credit stress virtually non-existent (HY OAS at 0.81%), institutions are aggressively bidding up this high-RS life sciences leader in a classic display of high-conviction price discovery.

Fired Signals

GOLDEN CROSSMARKET LEADERPERFECT STACKSMA BOUNCE

Key Takeaways

Actionable Thesis: Capitalize on the SMA_BOUNCE and PERFECT_STACK signals to enter long, riding the momentum from CRL's raised full-year guidance and expanding footprint in complex vaccine development.
Key Risk: Quantitative models currently flag the stock as overvalued, and recent insider selling by executives could act as a technical headwind.
What to Watch: Maintain a strict trailing stop or line-in-the-sand at $267.49; holding this level ensures the MARKET_LEADER structural uptrend remains intact.

← Back to 2026-09-03 View Full CRL History →Yahoo Finance &nearr;